Fabrizio Cavalca
Overview
Explore the profile of Fabrizio Cavalca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Civettini I, Zappaterra A, Corti P, Messina A, Aroldi A, Biondi A, et al.
Med
. 2024 Dec;
:100554.
PMID: 39701095
Background: Unstable hemoglobins are caused by single amino acid substitutions in the HBB gene, often affecting key histidine residues, leading to protein destabilization and hemolytic crises. In contrast, long HBB...
2.
Ripamonti A, Cavalca F, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli E
Cancer
. 2024 Nov;
131(1):e35638.
PMID: 39530681
Background: Myeloproliferative neoplasms represent a heterogeneous group of acquired hematopoietic stem cell diseases in which chronic inflammation is essential for both clonal evolution and thrombotic complications. The neutrophil-to-lymphocyte ratio (NLR),...
3.
Civettini I, Zappaterra A, Granelli B, Rindone G, Aroldi A, Bonfanti S, et al.
Br J Haematol
. 2023 Dec;
204(4):1523-1528.
PMID: 38070128
In a first-of-its-kind study, we assessed the capabilities of large language models (LLMs) in making complex decisions in haematopoietic stem cell transplantation. The evaluation was conducted not only for Generative...
4.
Palandri F, Palumbo G, Bonifacio M, Elli E, Tiribelli M, Auteri G, et al.
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894394
Most patients with myelofibrosis (MF) discontinue ruxolitinib (JAK1/JAK2 inhibitor) in the first 5 years of therapy due to therapy failure. As the therapeutic possibilities of MF are expanding, it is...
5.
Vergnano B, Signori D, Benini A, Calcinati S, Bettini F, Verga L, et al.
J Clin Med
. 2023 Oct;
12(19).
PMID: 37834926
Historically, the admission of hematological patients in the ICU shortly after the start of a critical illness is associated with better survival rates. Early intensive interventions administered by MET could...
6.
Coltro G, SantAntonio E, Palumbo G, Mannelli F, De Stefano V, Ruggeri M, et al.
Cancer Med
. 2023 Jan;
12(7):8166-8171.
PMID: 36708083
Background: Incorporating real-world data in the drug development process allows the improvement of health outcomes by providing better representation of actual patterns of drug safety and efficacy. Aims And Methods:...
7.
Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas M, et al.
Blood Cancer J
. 2022 Nov;
12(11):154.
PMID: 36379921
No abstract available.
8.
Bossi E, Aroldi A, Borin L, Verga L, Fontana D, Cocito F, et al.
EJHaem
. 2022 Oct;
PMID: 36248617
Hematological patients at higher risk of severe COVID-19 were excluded from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine trials. In this single-center observational prospective study (NCT05074706), we evaluate...
9.
Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas M, Elli E, et al.
Am J Hematol
. 2022 Sep;
97(12):E470-E473.
PMID: 36111658
No abstract available.
10.
Cattaneo D, Vener C, Elli E, Bucelli C, Galli N, Cavalca F, et al.
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406571
The 2016 WHO classification recognized pre-fibrotic primary myelofibrosis (pre-PMF) as a distinct entity. Nevertheless, a prognostic model specific for pre-PMF is still lacking. Our aim was to identify the most...